Tianyan Pharmaceuticals (ADAG, Financial) saw its stock price surge by 6.64%, reaching $2.25 per share with a trading volume of 62,168 shares. The stock's turnover rate was 0.14%, and its amplitude was 8.53%. Recent financials reported zero revenue, a net loss of $17.01 million, and an EPS of -$0.39, resulting in a PE ratio of -3.03. Among two rating institutions, 50% recommend buying, while the other 50% suggest holding.
In the biotechnology sector, where ADAG operates, the overall decline was 0.15%. Notable performers included Innate Pharma and 60 Degrees Pharmaceuticals, while Aptevo Therapeutics and Palisade Bio showed high activity. Tianyan Pharmaceuticals focuses on developing antibody-based cancer immunotherapies.
